Symmetric dimethylarginine inhibits renal fibrosis

Symmetric dimethylarginine (SDMA) is regarded as an independent cardiovascular risk factor in patients with chronic kidney diseases. Renal interstitial fibrosis is a common pathway of all kinds of chronic kidney diseases progressing to the end stage of renal diseases. In this study we investigated the role of SDMA in renal fibrosis and its underlining mechanisms.